Impact of silencing eEF2K expression on the malignant properties of chordoma
- PMID: 36652154
- DOI: 10.1007/s11033-023-08257-z
Impact of silencing eEF2K expression on the malignant properties of chordoma
Abstract
Background: Eukaryotic elongation factor 2 kinase (eukaryotic elongation factor 2 kinase, eEF2K) is a calcium calmodulin dependent protein kinase that keeps the highest energy consuming cellular process of protein synthesis under check through negative regulation. eEF2K pauses global protein synthesis rates at the translational elongation step by phosphorylating its only kown substrate elongation factor 2 (eEF2), a unique translocase activity in ekaryotic cells enabling the polypeptide chain elongation. Therefore, eEF2K is thought to preserve cellular energy pools particularly upon acute development of cellular stress conditions such as nutrient deprivation, hypoxia, or infections. Recently, high expression of this enzyme has been associated with poor prognosis in an array of solid tumor types. Therefore, in a growing number of studies tremendous effort is being directed to the development of treatment methods aiming to suppress eEF2K as a novel therapeutic approach in the fight against cancer.
Methods: In our study, we aimed to investigate the changes in the tumorigenicity of chordoma cells in presence of gene silencing for eEF2K. Taking a transient gene silencing approach using siRNA particles, eEF2K gene expression was suppressed in chordoma cells.
Results: Silencing eEF2K expression was associated with a slight increase in cellular proliferation and a decrease in death rates. Furthermore, no alteration in the sensitivity of chordoma cells to chemotherapy was detected in response to the decrease in eEF2K expression which intriguingly promoted suppression of cell migratory and invasion related properties.
Conclusion: Our findings indicate that the loss of eEF2K expression in chordoma cell lines results in the reduction of metastatic capacity.
Keywords: Chordoma; Migration; eEF2K; siRNAs.
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Molecular Mechanism for the Control of Eukaryotic Elongation Factor 2 Kinase by pH: Role in Cancer Cell Survival.Mol Cell Biol. 2015 May;35(10):1805-24. doi: 10.1128/MCB.00012-15. Epub 2015 Mar 16. Mol Cell Biol. 2015. PMID: 25776553 Free PMC article.
-
Eukaryotic elongation factor 2 (eEF2) kinase/eEF2 plays protective roles against glucose deprivation-induced cell death in H9c2 cardiomyoblasts.Apoptosis. 2019 Apr;24(3-4):359-368. doi: 10.1007/s10495-019-01525-z. Apoptosis. 2019. PMID: 30737648
-
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.Autophagy. 2014 Sep;10(9):1495-508. doi: 10.4161/auto.29164. Epub 2014 Jun 19. Autophagy. 2014. PMID: 24955726 Free PMC article.
-
Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.J Mol Med (Berl). 2020 Jun;98(6):775-787. doi: 10.1007/s00109-020-01917-8. Epub 2020 May 7. J Mol Med (Berl). 2020. PMID: 32377852 Review.
-
Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.Cell Stress Chaperones. 2015 Mar;20(2):217-20. doi: 10.1007/s12192-014-0545-0. Epub 2014 Sep 24. Cell Stress Chaperones. 2015. PMID: 25248493 Free PMC article. Review.
Cited by
-
Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma.J Neurooncol. 2025 Apr;172(2):307-315. doi: 10.1007/s11060-024-04920-y. Epub 2024 Dec 31. J Neurooncol. 2025. PMID: 39738914 Review.
References
-
- Chugh R, Tawbi H, Lucas DR et al (2007) Chordoma: the nonsarcoma primary bone tumor. Oncologist 12:1344–1350. https://doi.org/10.1634/theoncologist.12-11-1344 - DOI - PubMed
-
- Bell D, Raza SM, Bell AH et al (2016) Whole-transcriptome analysis of chordoma of the skull base. Virchows Arch 469:439–449. https://doi.org/10.1007/s00428-016-1985-y - DOI - PubMed
-
- Chambers KJ, Lin DT, Meier J et al (2014) Incidence and survival patterns of cranial chordoma in the United States. Laryngoscope 124:1097–1102. https://doi.org/10.1002/lary.24420 - DOI - PubMed
-
- Campbell RG, Prevedello DM, Ditzel Filho L et al (2015) Contemporary management of clival chordomas. Curr Opin Otolaryngol Head Neck Surg 23:153–161. https://doi.org/10.1097/MOO.0000000000000140 - DOI - PubMed
-
- Littman L, Reviews N (1856) Fletcher,14 Mabrey,28. 80–90
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous